KBY Biotech Indexv0.0.34
Search
← Pipeline|Ribosacituzumab

Ribosacituzumab

Approved
RHH-8046
By Roche
Source: Trial-derived·Trials: 4
Modality
Bispecific Ab
MOA
KIF18Ai
Target
Cl18.2
Pathway
Autophagy
DLBCL
Development Pipeline
Preclinical
~Dec 2010
→ ~Mar 2012
Phase 1
~Jun 2012
→ ~Sep 2013
Phase 2
~Dec 2013
→ ~Mar 2015
Phase 3
~Jun 2015
→ ~Sep 2016
NDA/BLA
~Dec 2016
→ ~Mar 2018
Approved
Jun 2018
→ Sep 2028
ApprovedCurrent
NCT07290098
1,616 pts·DLBCL
2018-06→2028-09·Active
NCT03093965
2,190 pts·DLBCL
2020-02→2025-08·Recruiting
NCT07722438
2,981 pts·DLBCL
2019-09→2027-06·Recruiting
+1 more trial
9,099 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2025-08-118mo agoPh3 Readout· DLBCL
2027-06-151.2y awayPh3 Readout· DLBCL
2028-09-202.5y awayPh3 Readout· DLBCL
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Active
Approved
Recruit…
Approved
Active
Approved
Recruit…
Catalysts
Ph3 Readout
2025-08-11 · 8mo ago
DLBCL
Ph3 Readout
2027-06-15 · 1.2y away
DLBCL
Ph3 Readout
2028-09-20 · 2.5y away
DLBCL
RecruitingActive|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT07290098ApprovedDLBCLActive1616CR
NCT03093965ApprovedDLBCLRecruiting2190EDSS
NCT07722438ApprovedDLBCLRecruiting2981NT-proBNP
NCT06475856ApprovedDLBCLActive2312VA
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-7550PfizerPhase 3AβKIF18Ai
MavutenlimabJohnson & JohnsonPhase 3Cl18.2Menini
JNJ-2735Johnson & JohnsonPhase 2/3Cl18.2MALT1i
RHH-8482RochePhase 1BTKKIF18Ai
PexatenlimabNovartisPhase 1/2GPRC5DKIF18Ai
AdagrazumabNovartisPhase 2/3Cl18.2EZH2i
ZorimavacamtenBristol-Myers SquibbPreclinicalCl18.2CDK4/6i
TAK-1836TakedaPreclinicalEGFRKIF18Ai
DoxafotisoranDaiichi SankyoPhase 1Cl18.2WEE1i
FixaglumideGenmabPhase 2/3WEE1KIF18Ai